Please Scroll Down to See Forums Below 
Preliminary Results of Serial hGH Radio-Immunoassays
Measuring Endogenous hGH Levels After Trans-D Tropin Administration
Rashid A. Buttar, DO and Dean C. Viktora, PhD
Serial hGH radio-immunoassay testing has clearly established rapid and direct increases in ENDOGENOUS hGH levels with Trans-D Tropin usage. This trans-dermal GH Releasing Hormone analog is the first hope of sustaining youthful and effective hGH levels naturally and conveniently.
The majority of published medical literature and current research have raised the question, if not definitively established the unreliability, of IGF-1 as an indicator of efficacy of hGH therapy. Documented clinical observations extensively support the research regarding unreliability of IGF-1 and perhaps, inappropriateness of IGF-1 testing for evaluation of effective hGH treatment.
The only definitive method for precise evaluation of GH treatment is by DIRECT MEASUREMENT of ENDOGENOUS hGH. However, this test usually is not obtained by the clinician. One reason for this is, up until now, no generally available GH therapeutic modality has ever been shown to effectively increase ENDOGENOUS hGH levels in a sustainable manner. As a result, the testing of hGH has usually been reserved for evaluation in hGH deficiency and short stature syndromes.
Another major reason why hGH levels have not been measured as a standard is because natural physiological release of ENDOGENOUS hGH is pulsatile. Therefore, the very transitory nature of ENDOGENOUS hGH makes it difficult to measure.
Average levels of ENDOGENOUS hGH were measurably increased per radio-immunoassay by over 750% within 30 minutes of Trans-D Tropin application. In some patients, there was even an increase in ENDOGENOUS hGH levels as early as 5 minutes post Trans-D Tropin application.
All three of the following EXAMPLES are patients considered hypo-responsive to stimulation of the pituitary by medical history, age and/or labs. The levels reported for all three patients were during first time usage of Trans-D Tropin, indicating the accelerated response attained by this trans-dermal hGH Releasing Hormone analog. The graph reflects combined data of all three patients.
75 y.o. critically ill female, discharged from the hospital after 3 week ICU stay, s/p CABG, with history of dilated cardiomyopathy. Due to age, medical condition and physiological stress, patient was not expected to respond. Baseline - 0.3 ng/ml, 5 min. - 0.3 ng/ml, 15 min. - 0.3 ng/ml, and 30 min. - 0.9 ng/ml. (200% )
13 y.o. adolescent male, previously tested with 2,3-butyrolactone and found to be hypo-responsive and with previous underlying history of hypothyroidism. No response was expected. Baseline - 0.3 ng/ml, 5 min. - 0.5 ng/ml, 15 min. - 2.3 ng/ml, and 30 min. - 2.2 ng/ml. (633% ).
54 y.o. male, in average health with no major medical history. Due to the age, patient was only expected to moderately respond to treatment. Baseline - 0.3 ng/ml, 5 min. - 0.5 ng/ml, 15 min. - 2.4 ng/ml, and 30 min. - 4.6 ng/ml. (1433% ).
The average baseline hGH radio-Immunoassays levels were 0.3 ng/ml prior to Trans-D Tropin. At 5 minutes after application, average levels were 0.43 ng/ml (44% increase). At 15 minutes post-treatment, levels were 1.67 ng/ml (456% increase). At 30 minutes post-treatment, levels increased to 2.57 ng/ml (756% increase). A multi-centered, double blind, placebo controlled, crossover study showing the results of over 350 patients using Trans-d Tropin should be available by spring.
Recombinant hGH injection therapy ONLY increases EXOGENOUS, SYNTHETIC GH levels and may induce negative inhibitory feed back DECREASING natural pituitary function. Trans-D Tropin is not only efficacious, but the safety, convenience, cost advantage, compliance and natural physiological emulation are factors NOT OFFERED by recombinant hGH injection therapy.
Measuring Endogenous hGH Levels After Trans-D Tropin Administration
Rashid A. Buttar, DO and Dean C. Viktora, PhD
Serial hGH radio-immunoassay testing has clearly established rapid and direct increases in ENDOGENOUS hGH levels with Trans-D Tropin usage. This trans-dermal GH Releasing Hormone analog is the first hope of sustaining youthful and effective hGH levels naturally and conveniently.
The majority of published medical literature and current research have raised the question, if not definitively established the unreliability, of IGF-1 as an indicator of efficacy of hGH therapy. Documented clinical observations extensively support the research regarding unreliability of IGF-1 and perhaps, inappropriateness of IGF-1 testing for evaluation of effective hGH treatment.
The only definitive method for precise evaluation of GH treatment is by DIRECT MEASUREMENT of ENDOGENOUS hGH. However, this test usually is not obtained by the clinician. One reason for this is, up until now, no generally available GH therapeutic modality has ever been shown to effectively increase ENDOGENOUS hGH levels in a sustainable manner. As a result, the testing of hGH has usually been reserved for evaluation in hGH deficiency and short stature syndromes.
Another major reason why hGH levels have not been measured as a standard is because natural physiological release of ENDOGENOUS hGH is pulsatile. Therefore, the very transitory nature of ENDOGENOUS hGH makes it difficult to measure.
Average levels of ENDOGENOUS hGH were measurably increased per radio-immunoassay by over 750% within 30 minutes of Trans-D Tropin application. In some patients, there was even an increase in ENDOGENOUS hGH levels as early as 5 minutes post Trans-D Tropin application.
All three of the following EXAMPLES are patients considered hypo-responsive to stimulation of the pituitary by medical history, age and/or labs. The levels reported for all three patients were during first time usage of Trans-D Tropin, indicating the accelerated response attained by this trans-dermal hGH Releasing Hormone analog. The graph reflects combined data of all three patients.
75 y.o. critically ill female, discharged from the hospital after 3 week ICU stay, s/p CABG, with history of dilated cardiomyopathy. Due to age, medical condition and physiological stress, patient was not expected to respond. Baseline - 0.3 ng/ml, 5 min. - 0.3 ng/ml, 15 min. - 0.3 ng/ml, and 30 min. - 0.9 ng/ml. (200% )
13 y.o. adolescent male, previously tested with 2,3-butyrolactone and found to be hypo-responsive and with previous underlying history of hypothyroidism. No response was expected. Baseline - 0.3 ng/ml, 5 min. - 0.5 ng/ml, 15 min. - 2.3 ng/ml, and 30 min. - 2.2 ng/ml. (633% ).
54 y.o. male, in average health with no major medical history. Due to the age, patient was only expected to moderately respond to treatment. Baseline - 0.3 ng/ml, 5 min. - 0.5 ng/ml, 15 min. - 2.4 ng/ml, and 30 min. - 4.6 ng/ml. (1433% ).
The average baseline hGH radio-Immunoassays levels were 0.3 ng/ml prior to Trans-D Tropin. At 5 minutes after application, average levels were 0.43 ng/ml (44% increase). At 15 minutes post-treatment, levels were 1.67 ng/ml (456% increase). At 30 minutes post-treatment, levels increased to 2.57 ng/ml (756% increase). A multi-centered, double blind, placebo controlled, crossover study showing the results of over 350 patients using Trans-d Tropin should be available by spring.
Recombinant hGH injection therapy ONLY increases EXOGENOUS, SYNTHETIC GH levels and may induce negative inhibitory feed back DECREASING natural pituitary function. Trans-D Tropin is not only efficacious, but the safety, convenience, cost advantage, compliance and natural physiological emulation are factors NOT OFFERED by recombinant hGH injection therapy.
